Editas Medicine, Inc. (EDIT) Social Stream
EDITAS MEDICINE INC (EDIT) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering EDITAS MEDICINE INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 13 | $80 | $30 | $54.909 | $11.26 | 387.65% |
| 2022-01-06 | 12 | $80 | $24 | $52.2 | $11.26 | 363.59% |
| 2022-01-31 | 12 | $80 | $16 | $51.4 | $11.26 | 356.48% |
| 2022-02-25 | 12 | $80 | $16 | $46.4 | $11.26 | 312.08% |
| 2022-02-28 | 11 | $80 | $16 | $41.777 | $11.26 | 271.02% |
| 2022-04-12 | 11 | $80 | $17 | $41.888 | $11.26 | 272.01% |
| 2022-04-26 | 11 | $80 | $17 | $41 | $11.26 | 264.12% |
| 2022-05-05 | 10 | $80 | $15 | $37.333 | $11.26 | 231.55% |
| 2022-05-09 | 10 | $80 | $15 | $37.111 | $11.26 | 229.58% |
| 2022-05-24 | 11 | $80 | $8 | $34.2 | $11.26 | 203.73% |
| 2022-08-05 | 12 | $80 | $8 | $30.1 | $11.26 | 167.32% |
| 2022-08-19 | 11 | $80 | $8 | $30.444 | $11.26 | 170.37% |
| 2022-10-12 | 12 | $80 | $8 | $29.2 | $11.26 | 159.33% |
| 2022-10-24 | 12 | $80 | $8 | $27.818 | $11.26 | 147.05% |
| 2022-11-02 | 12 | $80 | $8 | $27.545 | $11.26 | 144.63% |
| 2022-11-03 | 14 | $80 | $8 | $25.666 | $11.26 | 127.94% |
| 2022-11-08 | 14 | $80 | $8 | $25.25 | $11.26 | 124.25% |
| 2022-11-18 | 14 | $43 | $7 | $20.083 | $11.26 | 78.36% |
| 2022-12-06 | 14 | $35 | $7 | $16.166 | $11.26 | 43.57% |
| 2022-12-13 | 15 | $35 | $7 | $15.769 | $11.26 | 40.04% |
| 2023-01-04 | 16 | $36 | $7 | $16.642 | $11.26 | 47.8% |
| 2023-01-10 | 16 | $36 | $6 | $16.571 | $11.26 | 47.17% |
| 2023-01-16 | 16 | $36 | $6 | $15.142 | $11.26 | 34.48% |
| 2023-01-23 | 16 | $36 | $7 | $15.214 | $11.26 | 35.12% |
| 2023-01-27 | 16 | $36 | $7 | $15.142 | $11.26 | 34.48% |
| 2023-02-01 | 17 | $36 | $7 | $15.133 | $11.26 | 34.4% |
The Trend in the Analyst Price Target
EDIT's average price target has moved down $15.31 over the prior 170 days.
EDIT reports an average of 116.52% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-28 | 12 | 80 | 16 | 41.777 | 17.12 | 144.02% |
| 2022-05-05 | 10 | 80 | 15 | 37.333 | 14.56 | 156.41% |
| 2022-05-09 | 11 | 80 | 15 | 37.111 | 11.11 | 234.03% |
| 2022-08-05 | 12 | 80 | 8 | 30.100 | 19.42 | 54.99% |
| 2022-12-13 | 15 | 35 | 7 | 15.769 | 9.96 | 58.32% |
EDIT Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.57 | 6 | 0 | 8 | 2 | 2 | 17 |
The Trend in the Broker Recommendations
Over the past 13 months, EDIT's average broker recommendation rating worsened by 0.09.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for EDIT as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, EDITAS MEDICINE INC's variance in analysts' estimates is lower than -3368.73% of them.
- In terms of how EDITAS MEDICINE INC fares relative to stocks in the mid market cap category, note that its number of analysts covering the stock is greater than 3253.42% of that group.
- In terms of how EDITAS MEDICINE INC fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is greater than 2923.64% of that group.
- In terms of how EDITAS MEDICINE INC fares relative to stocks in the mid market cap category, note that its average analyst price target is greater than 1464.35% of that group.
Stocks similar to EDITAS MEDICINE INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RGNX, FATE, and IOVA.
View All Top Stocks by Price Target
Is EDIT a Buy, Hold or Sell? See the POWR Ratings now!